• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Levodopa Pharmacokinetics in Switching From Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report.

作者信息

Nukariya Tomonori, Tezuka Toshiki, Okusa Shohei, Okochi Ryotaro, Sakai Yuto, Nihei Yoshihiro, Nakahara Jin, Seki Morinobu

机构信息

Department of Neurology, Keio University School of Medicine, Tokyo, Japan.

Parkinson's Disease Center, Keio University Hospital, Tokyo, Japan.

出版信息

J Mov Disord. 2025 Apr;18(2):179-181. doi: 10.14802/jmd.24247. Epub 2025 Jan 6.

DOI:10.14802/jmd.24247
PMID:39757596
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12061616/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a37/12061616/9ac3e1a70d7e/jmd-24247f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a37/12061616/9ac3e1a70d7e/jmd-24247f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a37/12061616/9ac3e1a70d7e/jmd-24247f1.jpg

相似文献

1
Levodopa Pharmacokinetics in Switching From Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report.帕金森病患者从左旋多巴/卡比多巴肠凝胶转换为持续皮下注射左旋多巴甲酯/卡比多巴甲酯的左旋多巴药代动力学：病例报告
J Mov Disord. 2025 Apr;18(2):179-181. doi: 10.14802/jmd.24247. Epub 2025 Jan 6.
2
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.晚期帕金森病患者连续皮下注射左多巴-卡比多巴的安全性和有效性：一项随机、双盲、阳性对照、3 期临床试验。
Lancet Neurol. 2022 Dec;21(12):1099-1109. doi: 10.1016/S1474-4422(22)00400-8.
3
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum.福司列弗多巴/卡比多巴皮下输注与左旋多巴-卡比多巴肠凝胶输送至空肠的暴露量等效。
Parkinsonism Relat Disord. 2022 Apr;97:68-72. doi: 10.1016/j.parkreldis.2022.03.012. Epub 2022 Mar 22.
4
Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson's Disease.左旋多巴/卡比多巴肠凝胶：晚期帕金森病的综述
CNS Drugs. 2025 Jun;39(6):621-632. doi: 10.1007/s40263-025-01179-3. Epub 2025 Apr 8.
5
Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion.福司列弗多巴/福卡比多巴经皮下输注后具有良好的耐受性，并能维持稳定的左旋多巴和卡比多巴暴露量。
J Parkinsons Dis. 2021;11(4):1695-1702. doi: 10.3233/JPD-212813.
6
Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel.采用 LC-HRMS 对健康人体参与者血浆中的 foslevodopa/foscarbidopa 进行代谢物分析，结果表明与给予左旋多巴/卡比多巴肠凝胶相比无明显差异。
Pharmacol Res Perspect. 2024 Apr;12(2):e1190. doi: 10.1002/prp2.1190.
7
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.帕金森病患者皮下持续输注左旋多巴/卡比多巴：一项为期12个月的单臂、开放标签3期研究的安全性和有效性结果
Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26.
8
Continuous Subcutaneous Foslevodopa-Foscarbidopa in Parkinson's Disease: A Mini-Review of Current Scope and Future Outlook.帕金森病中持续皮下注射左多巴-卡比多巴：当前范围和未来展望的小型综述。
Mov Disord Clin Pract. 2024 Oct;11(10):1188-1194. doi: 10.1002/mdc3.14161. Epub 2024 Jul 11.
9
Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease.福司列弗多巴/福卡多巴：帕金森病的一种新皮下治疗方法。
Ann Neurol. 2021 Jul;90(1):52-61. doi: 10.1002/ana.26073. Epub 2021 May 4.
10
Comparability of Foslevodopa/Foscarbidopa Pharmacokinetics in Healthy Asian and White Participants.福沙左旋多巴/福沙卡比多巴在健康亚洲和白人受试者中药代动力学的可比性
Clin Pharmacol Drug Dev. 2023 Apr;12(4):407-415. doi: 10.1002/cpdd.1201. Epub 2022 Nov 16.

引用本文的文献

1
Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease.左旋多巴/卡比多巴复方制剂对帕金森病患者认知及精神方面的不良影响
Mov Disord Clin Pract. 2025 Jul;12(7):1028-1030. doi: 10.1002/mdc3.70060. Epub 2025 Mar 28.

本文引用的文献

1
Continuous Subcutaneous Foslevodopa-Foscarbidopa in Parkinson's Disease: A Mini-Review of Current Scope and Future Outlook.帕金森病中持续皮下注射左多巴-卡比多巴：当前范围和未来展望的小型综述。
Mov Disord Clin Pract. 2024 Oct;11(10):1188-1194. doi: 10.1002/mdc3.14161. Epub 2024 Jul 11.
2
Potential Psychosis Induced by a Sustained High Plasma Levodopa Concentration Due to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report.帕金森病患者持续皮下输注福司来沃多巴/福司卡比多巴导致血浆左旋多巴浓度持续升高引发潜在精神病：一例报告
J Mov Disord. 2024 Oct;17(4):453-455. doi: 10.14802/jmd.24114. Epub 2024 Jun 28.
3
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance.
持续皮下输注左旋多巴/卡比多巴用于治疗帕金森病的运动波动：起始和维持的注意事项
Clin Park Relat Disord. 2024 Feb 10;10:100239. doi: 10.1016/j.prdoa.2024.100239. eCollection 2024.
4
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.帕金森病患者皮下持续输注左旋多巴/卡比多巴：一项为期12个月的单臂、开放标签3期研究的安全性和有效性结果
Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26.
5
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals.帕金森病中的左旋多巴剂量等效：更新的系统评价和建议。
Mov Disord. 2023 Jul;38(7):1236-1252. doi: 10.1002/mds.29410. Epub 2023 May 5.
6
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.晚期帕金森病患者连续皮下注射左多巴-卡比多巴的安全性和有效性：一项随机、双盲、阳性对照、3 期临床试验。
Lancet Neurol. 2022 Dec;21(12):1099-1109. doi: 10.1016/S1474-4422(22)00400-8.
7
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum.福司列弗多巴/卡比多巴皮下输注与左旋多巴-卡比多巴肠凝胶输送至空肠的暴露量等效。
Parkinsonism Relat Disord. 2022 Apr;97:68-72. doi: 10.1016/j.parkreldis.2022.03.012. Epub 2022 Mar 22.
8
Challenges in the diagnosis of Parkinson's disease.帕金森病诊断中的挑战。
Lancet Neurol. 2021 May;20(5):385-397. doi: 10.1016/S1474-4422(21)00030-2.
9
Levodopa challenge test: indications, protocol, and guide.左旋多巴激发试验：适应症、方案及指南。
J Neurol. 2021 Sep;268(9):3135-3143. doi: 10.1007/s00415-020-09810-7. Epub 2020 Apr 24.
10
Diagnosis and Treatment of Parkinson Disease: A Review.帕金森病的诊断与治疗：综述。
JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360.